Business Context and Reporting Period
This Form 8-K is filed by Enochian BioSciences Inc. (not Lunai Bioworks Inc.) on December 27, 2022. The report addresses a regulatory event concerning the company's listing status on The Nasdaq Stock Market LLC under the trading symbol ENOB.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The material change reported is the resolution of a listing deficiency. On December 16, 2022, the company submitted a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1). On December 27, 2022, Nasdaq granted an exception to the company, allowing it time to regain compliance.
Guidance, Outlook, and Risks
Compliance Requirements: To maintain the granted exception, the company must file the following with the SEC by April 11, 2023:
- Annual Report on Form 10-K for the fiscal year ended June 30, 2022.
- Quarterly Report on Form 10-Q for the period ended September 30, 2022.
- All other filings required by the Rule.
Risks: Failure to meet these filing deadlines could result in the loss of the exception and potential delisting from Nasdaq.
Investor Verification Checklist
- Verify the company name is Enochian BioSciences Inc. (ENOB), not Lunai Bioworks Inc.
- Confirm the submission of the Form 10-K (FY ended June 30, 2022) and Form 10-Q (Q ended Sept 30, 2022) by the April 11, 2023 deadline.
- Monitor subsequent Nasdaq communications regarding the final restoration of compliance.